Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $465M. The Maz Rating grades it against the other companies in its sector.
Aquestive Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.70, Aquestive Therapeutics, Inc. trades at 9.5x sales. Over the last twelve months it generated about $49M of revenue and a net loss of $81M. It runs a gross margin of 65.3%, an operating margin of -114.1% and a net margin of -162.3%. It shows return on equity of 255.1%, return on invested capital of -54.3% and a free cash flow yield of -8.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.12. Over the past 52 weeks the share price ranged from $2.93 to $6.74, with a beta of 1.50.
Aquestive Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.